CONFERENCE DAY TWO

Thursday October 2, 2025

7:50 am Check In & Light Breakfast

8:50 am Chair’s Opening Remarks

Defining Gold-Standard Methodologies & Establishing Consensus for Omics Analysis to Facilitate Effective Downstream Multi-Omics Capabilities

9:00 am Multimodal Network Approach for Discovery of Novel Targets in Rheumatoid Arthritis

Synopsis

  • Gene module network is deconstructed using scRNAseq data from RA patient samples.
  • Highly multiplexed spatial omics approach (CosMx) recapitulated granular cell types in space.
  • Spatial domain (niche) highlighted unique spatial interactions in RA

9:30 am Roundtable Discussion: Working Effectively with Challenging Samples to Achieve Maximum Multi-Omics Insight from Low Quality & Quantity Data

  • Elsa Molina Director, Single-Cell & Spatial Omics Core, Salk Institute of Biological Studies

Synopsis

  • Overcoming low data availability by combining omics data from different populations with the same disease and accounting for unbalanced and unnormalized data
  • Upholding high quality control standards during assay development, sample collection, processing and storage to avoid damaging or wasting patient data
  • Integrating protocols in preclinical and clinical development to ensure adequate sample collection and annotation

10:15 am Morning Break & Networking

Dissecting the Biology & Evolution of Disease with Multi-Omics Insights to Transform Pathology & Drug Discovery

11:15 am Acquiring Principles of Spatial Data Deconvolution & Interpretation: Building a Novel Paradigm to Characterize Inflammatory Bowel Disease

Synopsis

  • Development of a novel computational model to reconcile with the complex spatiotemporal nature of data and extract disease-relevant insights from human FFPE tissues.
  • Integration of spatial biology with quantitative histopathology to characterize the nature of inflammation present in various cellular niches.
  • Trajectory inference and pseudo-time analysis to study the epithelial barrier dysfunction during IBD.

11:45 am From Data to Depletion: Integrating Multi-Omics, Computation & Experimental Validation to Identify & Eliminate Pathogenic Cell Populations

  • Adam Freund Founder & Chief Executive Officer, Arda Therapeutics

Synopsis

  • Harnessing multi-modal single-cell, spatial, and genetic data to pinpoint disease-driving cell populations and their surface vulnerabilities
  • Bridging in silico discovery with in vivo validation through a tightly integrated platform of custom biologics and cell depletion assays
  • Accelerating therapeutic development by comparing targets and modalities head-to head in disease-relevant models to nominate the best path forward

12:15 pm Single Cell Multimodal Analysis Reveals Cell-Cell Communication Networks in Normal & Abnormal Cardiac Morphogenesis

Synopsis

  • Integrated single-cell RNA-seq and ATAC-seq atlas of mouse heart development over 5 timepoints
  • Development of a machine learning classification algorithm to discover transcriptional enhancers for cell types
  • Applications of integrated multimodal analyses to define mechanisms of congenital heart defects

12:45 pm Lunch Break & Networking

Unlocking Previously Undruggable Targets with Multi-Omics to Revolutionize Treatment Strategy & Precision Medicine & Reach More Patients in Need

1:45 pm Multimodal Profiling of FFPE Tissue to Characterize Disease Biology & Enable Novel Early Target Identification in Crohn’s Disease

  • Anjali Rao Senior Scientist - Bioinformatics, Gilead Sciences

Synopsis

  • Integrating histological and transcriptomic information to increase understanding of disease biology and drive new target discovery
  • Taking advantage of the technological innovation that allows matched single-nuclei RNAseq, spatial transcriptomics, and multiplex immunofluorescence from FFPE tissue and applying this to a curated patient cohort
  • Using advanced bioinformatics analysis and histologically guided features to report a novel framework to guide target discovery in inflammatory diseases

2:15 pm Uncovering Novel Drug Targets in Giant Cell Arteritis Through Spatial Transcriptomics

  • Elsa Molina Director, Single-Cell & Spatial Omics Core, Salk Institute of Biological Studies

Synopsis

  • Dissecting the Cellular and Molecular Landscape of Giant Cell Arteritis (GCA) Using Single-Cell Spatial Transcriptomics
  • Technical Landscape: Comparative Overview of Spatial Transcriptomics Platforms
  • Identifying Novel Therapeutic Targets in GCA through Spatially Resolved Pathway Analysis

2:45 pm Multi-Omics for Precision Medicine: Applying Complex Analysis of Individual Patient Data to Guide Development of Efficacious, Tolerable Personalized Therapies

  • Andrew Parton Associate Director - Data Science, MultiOmic Health

Synopsis

  • Developing comprehensive analytical methodologies to create a multi-omics picture of an individual patient
  • Tracking patient response with AI to multi-omics-based decisions to validate findings and inform future care
  • Lessons on applying multi-omics to personalised medicine pipelines

3:15 pm Multi-Omics Discovery & In Vivo Validation of Novel Targets for Neurology & Oncology

  • Aarash Bordbar Co-Founder, Chief Technology Officer, Sinopia Biosciences

Synopsis

  • Applying a data-driven approach to drug discovery by integrating large-scale multi-omics datasets with advanced AI/ML tools to uncover biology and discover novel therapeutic targets
  • Discovery and development of SB-0110, a first-in-class small molecule for Parkinson’s disease and levodopa-induced dyskinesia
  • Generating and deploying metabolomics-based models for drug discovery, demonstrating superior performance to transcriptomics in initial applications

3:45 pm Throwing the Kitchen Sink at Drug Development for Autoimmune Diseases

  • Bryan Linggi Senior Director - Translational Medicine, AnaptysBio

Synopsis

  • Strengths and limitations of multi-omics
  • Digestible multi-omics
  • Case study for Ulcerative Colitis

4:15 pm Chair’s Closing Remarks

4:30 pm End of Multi-Omics Based Drug Discovery & Development Summit